| Patient | Yul Brynner |
|---|---|
| Date of birth | 1963-07-11 |
| Identifiers | MRN HR-ML020-SYN; SSN (made up) 000-20-4572 |
| Document date | 2026-10-20 |
| Author | Simon Achterberg, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Itchy rash on the chest, back, and arms for four days, during pembrolizumab treatment. [S]
Mr. Brynner is a 63-year-old man with stage IVB adenocarcinoma of the left upper lobe (PD-L1 70 percent, no actionable alteration) who had his second pembrolizumab infusion one week ago and his first zoledronic acid dose the same day. He asked for a same-day visit for an itchy rash. Four days ago he noticed small red bumps on his chest that have spread to his upper back and the inner arms. The itching is worst at night and in the heat of the stage lights at rehearsal, but he is sleeping. He has had no blisters, peeling, mouth or eye soreness, genital sores, or fever. The aches he had for a day after the zoledronic acid dose have gone. He has started no new soap, detergent, or medicine other than the infusions. He has had no diarrhea, abdominal pain, cough, breathlessness, headache, unusual fatigue, or yellowing of the skin or eyes. His voice remains improved since the injection two weeks ago. [S]
| Element | Detail |
|---|---|
| Onset | Four days ago, three and a half weeks after the first pembrolizumab dose and three days after the second |
| Location | Chest, upper back, and inner arms; face, palms, soles, and mucous membranes spared |
| Duration | Four days, slowly spreading |
| Character | Small red raised spots that join in places; itchy |
| Severity | Mild; about 8 percent of body surface area; sleeping and working |
| Timing | Itching worst at night and under hot stage lights |
| Context | On pembrolizumab every 3 weeks; first zoledronic acid dose one week ago; no new exposures |
| Modifying factors | Cool showers help; nothing taken |
| Associated signs and symptoms | Denies fever, blisters, mucosal sores, diarrhea, cough, breathlessness, headache, and jaundice |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever, chills, or unusual fatigue |
| Integumentary | Positive | Itchy red rash on the trunk and arms; no blisters or peeling |
| Eyes | Negative | No redness, pain, or change in vision |
| Ears, nose, mouth, and throat | Negative | No mouth sores; voice improved |
| Respiratory | Negative | No new cough or breathlessness |
| Gastrointestinal | Negative | No diarrhea, abdominal pain, or dark urine |
| Endocrine | Negative | No headache, dizziness, heat or cold intolerance, or excessive thirst |
7 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Pembrolizumab 200 mg intravenous infusion over 30 minutes every 3 weeks | Every 3 weeks in the oncology infusion unit, after the immune-related adverse event laboratory panel | Intravenous route | 2026-09-22 | active | S |
| Zoledronic acid 4 mg in 100 mL intravenous infusion over 15 minutes every 12 weeks, for bone metastases | Every 12 weeks, after calcium and creatinine, with a dental examination done first | Intravenous route | 2026-10-13 | active | S |
| Cholecalciferol (vitamin D3) 25 mcg (1000 units) oral tablet, one tablet daily, with calcium from food, while on zoledronic acid | One tablet by mouth daily | Oral route | 2026-10-13 | active | S |
| Triamcinolone acetonide 0.1% cream, thin layer to the rash twice daily for two weeks (not on the face or skin folds) | Apply a thin layer twice daily for up to two weeks | Topical route | 2026-10-20 | active | S |
| Cetirizine 10 mg oral tablet, one tablet daily as needed for itching | One tablet by mouth daily as needed for itching | Oral route | 2026-10-20 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-10-20 | Body height | 178 | cm | S |
| 2026-10-20 | Body weight | 72 | kg | S |
| 2026-10-20 | Body mass index (BMI) [Ratio] | 22.7 | kg/m2 | S |
| 2026-10-20 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-10-20 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-10-20 | Heart rate | 78 | /min | S |
| 2026-10-20 | Respiratory rate | 16 | /min | S |
| 2026-10-20 | Body temperature | 36.7 | Cel | S |
| 2026-10-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-10-20 | Thyrotropin [Units/volume] in Serum or Plasma | 2.6 | m[IU]/L | 0.4-4 mIU/L | Normal | S |
| 2026-10-20 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1.1 | ng/dL | 0.8-1.8 ng/dL | Normal | S |
| 2026-10-20 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 28 | U/L | 7-55 U/L | Normal | S |
| 2026-10-20 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 25 | U/L | 8-48 U/L | Normal | S |
| 2026-10-20 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-10-20 | Creatinine [Mass/volume] in Serum or Plasma | 0.9 | mg/dL | 0.7-1.3 mg/dL | Normal | S |
| 2026-10-20 | Eosinophils [#/volume] in Blood by Automated count | 0.62 | 10*3/uL | 0-0.5 10*3/uL | High | S |
Vital signs recorded on 2026-10-20; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well and comfortable; afebrile at 36.7 °C |
| Skin | Discrete and partly joined pink macules and papules over the anterior chest, upper back, and inner upper arms, about 8 percent of body surface area; scratch marks; no blisters, target lesions, skin pain, or peeling; Nikolsky sign negative |
| Mucous membranes | Mouth, lips, and eyes normal |
| Lymph nodes | No new enlargement |
| Lungs | Clear; oxygen saturation 97 percent |
| Abdomen | Soft and non-tender; no liver enlargement |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Adenocarcinoma of the left upper lobe of the lung, stage IVB (cT4 N2 M1c, AJCC 8th edition), unresectable: the primary invades the mediastinum at the aortopulmonary window; bone metastases; PD-L1 tumor proportion score 70 percent (22C3); ECOG performance status 1; comprehensive genomic profiling results in the notes | active | confirmed | C34.12 | S — Synthetic modern histology, stage, and biomarkers linked to his documented inoperable lung cancer of September 1983. |
| Bone metastases at T10, the right ilium, and the left sixth rib on PET-CT, without pain, fracture, or cord compression | active | confirmed | C79.51 | S — Synthetic metastatic sites chosen so that first-line systemic therapy is the standard of care; no source describes the spread of his cancer. |
| Left vocal fold paralysis with a breathy, weak voice, most likely from left recurrent laryngeal nerve involvement by disease in the aortopulmonary window | active | confirmed | J38.01 | S — Synthetic laryngoscopy finding anchored to the published account that a vocal-cord problem led to his diagnosis; the lay 'lump on his vocal cords' is not modeled as a laryngeal tumor. |
| Left upper lobe mass invading the mediastinum, with enlarged mediastinal lymph nodes, on CT at presentation; suspicious for lung cancer pending tissue diagnosis | active | confirmed | R91.8 | S — Synthetic presenting imaging finding, recorded before the tissue diagnosis. |
| Former smoker: about 3 packs a day from age 12 until he quit 12 years ago, roughly 115 pack-years; no tobacco since | active | confirmed | Z87.891 | S — Synthetic modern entry linked to the documented heavy smoking and quitting; the pack-year figure is a synthetic midpoint of conflicting published amounts. |
| Immune-related maculopapular rash from pembrolizumab, grade 1 (about 8 percent of body surface area, itchy, no blisters or mucosal involvement) | active | confirmed | L27.0 | S — Synthetic common immune-related adverse event on checkpoint inhibitor therapy. |
Guideline basis: CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026); NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026); Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (2021)
Follow-up: Skin check at the preventive visit next week, or sooner as above. Cycle 3 in two weeks. Next scheduled visit 2026-10-27: periodic adult preventive visit. [S]